Davy Research

Malin Corporation

Melinta reverse merger with Cempra Inc.
Pharma and healthcare
Malin Corporation

DAVY VIEW

We are positive on Melinta’s proposed merger with Cempra Inc. The new entity will have a broad portfolio of innovative anti-infective offerings. This is an important area given increasing resistance levels to traditional antibiotics. Melinta should also benefit from Cempra’s balance sheet strength (cash c.$203m) in bringing its pipeline to market. Although Malin’s shareholding in the combined entity is initially dilutive, we believe that the market should react favourably over time to Melinta’s promising pipeline and the integrated anti-infectives platform the merger creates.

Download full report with analyst certification and important disclosures
Download
Download full report with analyst certification and important disclosures
Download
  • RATINGS AND PRICE CORRECT AT TIME OF ISSUE


  • Malin Corporation

    Closing Price: 1200c

  • RATING 29/09/15

  • PREVIOUS RATING N/A

Analyst(S)

COMPANY DATA

JUMP TO